Non-invasive diagnosis of liver fibrosis in chronic hepatitis C

Table 3 Most studied models combining direct and indirect biomarkers for the diagnosis of liver fibrosis in chronic hepatitis C

Score (original reference)	Variables	Performance in HCV patients1
		Significant fibrosis (≥F2)			Cirrhosis (≥F4)
		Median AUROC	Median sensitivity2	Median specificity2	Median AUROC	Median sensitivity2	Median specificity2
FibroTest[53]	Age, sex, serum haptoglobin, α2-macroglobulin, apolipoprotein A1, GGT, and total bilirubin	0.79	92%	96%	0.86	85%	81%
ELF[56]	Age, TIMP-1, PIIINP and hyaluronic acid	0.81	85%	70%	0.88	-	-
Fibrometer[61]	Platelet count, prothrombin index, AST, α2-macroglobulin, hyaluronic acid, blood urea nitrogen and age	0.82	69%	81%	0.91	-	-
FIBROspect II[63]	TIMP-1, α2-macroglobulin and hyaluronic acid	0.86	80%	70%	-	-	-
Hepascore[66]	Age, sex, α2-macroglobulin, hyaluronic acid, GGT and total bilirubin	0.79	66%	79%	0.89	72%	86%

¹Based on reference number 49;

²Sensitivity values are presented for the lower cutoff and specificity for the upper cutoff (when multiple cutoffs are presented). ELF: Enhanced liver fibrosis; HCV: Hepatitis C virus; AUROC: Area under the receiver operating characteristic curve; GGT: Gamma-glutamyltransferase; TIMP: Tissue inhibitor of matrix metalloproteinases; PIIINP: Procollagen type III amino-terminal peptide; AST: Aspartate aminotransferase.